name: Beta Thalassemia
category: Mendelian
parents:
- Hematological Disease
- Genetic Disease
disease_term:
  preferred_term: beta thalassemia
  term:
    id: MONDO:0019402
    label: beta thalassemia
has_subtypes:
- name: Beta Thalassemia Minor (Trait)
  description: >
    Heterozygous carriers with one normal and one affected HBB allele.
    Usually asymptomatic or mild microcytic anemia. Identified by elevated HbA2.
- name: Beta Thalassemia Intermedia
  description: >
    Moderate disease severity, typically homozygous or compound heterozygous
    for mild HBB mutations. Patients may require intermittent transfusions.
- name: Beta Thalassemia Major (Cooley Anemia)
  description: >
    Severe transfusion-dependent anemia due to homozygous or compound
    heterozygous severe HBB mutations. Presents in first 1-2 years of life.
prevalence:
- population: Global carriers
  percentage: 1.5
  notes: >
    Estimated 1.5% of the global population are heterozygous carriers.
    Highest prevalence occurs in the Mediterranean basin, Middle East,
    Indian subcontinent, Southeast Asia, and Melanesia.
  evidence:
  - reference: PMID:28293406
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Approximately 1.5% of the global population are heterozygotes (carriers)
      of the β-thalassemias; there is a high incidence in populations from the Mediterranean
      basin, throughout the Middle East, the Indian subcontinent, Southeast Asia,
      and Melanesia to the Pacific Islands."
    explanation: Supports the stated global carrier prevalence and its 
      geographic concentration.
inheritance:
- name: Autosomal recessive
pathophysiology:
- name: Defective Beta-Globin Synthesis
  description: >
    Mutations in the HBB gene reduce or abolish beta-globin chain production.
    Beta-zero (beta0) mutations produce no beta-globin; beta-plus (beta+)
    mutations produce reduced amounts. Over 300 mutations have been identified,
    including point mutations, small deletions, and rarely large deletions.
  genes:
  - preferred_term: HBB
    term:
      id: hgnc:4827
      label: HBB
  biological_processes:
  - preferred_term: hemoglobin biosynthetic process
    modifier: DECREASED
    term:
      id: GO:0042541
      label: hemoglobin biosynthetic process
  cell_types:
  - preferred_term: erythroblast
    term:
      id: CL:0000765
      label: erythroblast
  downstream:
  - target: Alpha-Globin Chain Excess
    description: >
      Reduced beta-globin leads to unpaired alpha-globin chains that
      precipitate and damage erythroid precursors.
  evidence:
  - reference: PMID:20492708
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Beta-thalassemias are caused by point mutations or, more rarely, deletions
      in the beta globin gene on chromosome 11, leading to reduced (beta+) or absent
      (beta0) synthesis of the beta chains of hemoglobin (Hb)."
    explanation: Confirms that HBB mutations lead to reduced or absent 
      beta-globin chain synthesis.
- name: Alpha-Globin Chain Excess
  description: >
    Excess unpaired alpha-globin chains precipitate as insoluble aggregates
    in erythroid precursors, causing oxidative membrane damage, apoptosis
    of erythroblasts (ineffective erythropoiesis), and shortened survival
    of mature red blood cells (hemolysis). This is the central pathogenic
    mechanism distinguishing beta-thalassemia from alpha-thalassemia.
  genes:
  - preferred_term: HBA1
    term:
      id: hgnc:4823
      label: HBA1
  - preferred_term: HBA2
    term:
      id: hgnc:4824
      label: HBA2
  biological_processes:
  - preferred_term: response to oxidative stress
    modifier: INCREASED
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  cell_types:
  - preferred_term: erythroblast
    term:
      id: CL:0000765
      label: erythroblast
  downstream:
  - target: Ineffective Erythropoiesis
    description: >
      Apoptosis of alpha-chain-laden erythroid precursors in the bone marrow.
  - target: Chronic Hemolysis
    description: >
      Surviving erythrocytes with membrane damage are cleared prematurely.
  evidence:
  - reference: PMID:21705976
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "unbalanced alpha globin chain synthesis results in severely rheologically
      compromised erythrocytes with premature destruction in the peripheral circulation
      and ineffective erythropoiesis within the bone marrow and in extramedullary
      sites"
    explanation: Confirms that excess alpha-globin chains cause both peripheral 
      erythrocyte destruction and ineffective erythropoiesis.
- name: Ineffective Erythropoiesis
  description: >
    Massive expansion of erythroid precursors in bone marrow and
    extramedullary sites, but most cells undergo apoptosis before
    maturing. This drives erythroid hyperplasia, skeletal deformities
    (marrow expansion), and inappropriately low reticulocyte output
    relative to the degree of erythroid expansion.
  biological_processes:
  - preferred_term: erythrocyte differentiation
    modifier: ABNORMAL
    term:
      id: GO:0030218
      label: erythrocyte differentiation
  - preferred_term: erythrocyte homeostasis
    modifier: ABNORMAL
    term:
      id: GO:0034101
      label: erythrocyte homeostasis
  cell_types:
  - preferred_term: erythroid progenitor cell
    term:
      id: CL:0000038
      label: erythroid progenitor cell
  downstream:
  - target: Iron Overload
    description: >
      Ineffective erythropoiesis suppresses hepcidin, increasing
      intestinal iron absorption and leading to iron overload even
      without transfusions.
  evidence:
  - reference: PMID:22631035
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ineffective erythropoiesis is the hallmark of beta-thalassemia that
      triggers a cascade of compensatory mechanisms resulting in clinical sequelae
      such as erythroid marrow expansion, extramedullary hematopoiesis, splenomegaly,
      and increased gastrointestinal iron absorption."
    explanation: Confirms ineffective erythropoiesis as the hallmark mechanism 
      driving marrow expansion, extramedullary hematopoiesis, and iron 
      absorption.
- name: Chronic Hemolysis
  description: >
    Peripheral destruction of abnormal erythrocytes with membrane damage
    from precipitated alpha-globin chains. Leads to anemia, jaundice,
    splenomegaly, and gallstones.
  biological_processes:
  - preferred_term: erythrocyte homeostasis
    modifier: ABNORMAL
    term:
      id: GO:0034101
      label: erythrocyte homeostasis
  - preferred_term: positive regulation of erythrocyte clearance
    modifier: INCREASED
    term:
      id: GO:0034108
      label: positive regulation of erythrocyte clearance
  cell_types:
  - preferred_term: erythrocyte
    term:
      id: CL:0000232
      label: erythrocyte
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  downstream:
  - target: Iron Overload
    description: Iron released from hemolyzed red cells contributes to iron 
      loading.
  evidence:
  - reference: PMID:21705976
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "unbalanced alpha globin chain synthesis results in severely rheologically
      compromised erythrocytes with premature destruction in the peripheral circulation"
    explanation: Confirms peripheral destruction of rheologically compromised 
      erythrocytes (hemolysis).
- name: Iron Overload
  description: >
    Iron accumulation from transfusional hemosiderosis and increased
    intestinal absorption (due to hepcidin suppression from ineffective
    erythropoiesis). Iron deposits in heart, liver, and endocrine organs
    cause cardiomyopathy, liver fibrosis, diabetes, and hypogonadism.
  genes:
  - preferred_term: HAMP
    term:
      id: hgnc:15598
      label: HAMP
  biological_processes:
  - preferred_term: intracellular iron ion homeostasis
    modifier: ABNORMAL
    term:
      id: GO:0006879
      label: intracellular iron ion homeostasis
  - preferred_term: iron ion transport
    modifier: INCREASED
    term:
      id: GO:0006826
      label: iron ion transport
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  evidence:
  - reference: PMID:21705976
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "erythropoiesis,anemia and hypoxia down-regulate hepcidin, the master
      regulator of iron homeostasis. Hepcidin deficiency in turn allows excessive
      duodenal iron absorption and development of systemic iron overload."
    explanation: Confirms hepcidin suppression from ineffective erythropoiesis 
      as the mechanism of iron overload.
  - reference: PMID:20492708
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Regular transfusion therapy leads to iron overload-related complications
      including endocrine complication (growth retardation, failure of sexual maturation,
      diabetes mellitus, and insufficiency of the parathyroid, thyroid, pituitary,
      and less commonly, adrenal glands), dilated myocardiopathy, liver fibrosis and
      cirrhosis)"
    explanation: Confirms iron overload complications affecting heart, liver, 
      and endocrine organs.
- name: Fetal Hemoglobin Modulation
  description: >
    Genetic modifiers that increase fetal hemoglobin (HbF) production
    ameliorate disease severity by compensating for deficient adult
    hemoglobin (HbA) and reducing free alpha-globin chains. Key modifiers
    include BCL11A, HBS1L-MYB locus, and KLF1.
  genes:
  - preferred_term: BCL11A
    term:
      id: hgnc:13221
      label: BCL11A
  - preferred_term: KLF1
    term:
      id: hgnc:6345
      label: KLF1
  - preferred_term: MYB
    term:
      id: hgnc:7545
      label: MYB
  - preferred_term: HBS1L
    term:
      id: hgnc:4834
      label: HBS1L
  biological_processes:
  - preferred_term: regulation of hemoglobin biosynthetic process
    term:
      id: GO:0046984
      label: regulation of hemoglobin biosynthetic process
  cell_types:
  - preferred_term: erythroid progenitor cell
    term:
      id: CL:0000038
      label: erythroid progenitor cell
  evidence:
  - reference: PMID:18691915
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "In this study, we showed that SNPs in BCL11A were associated with F-cell
      numbers in Chinese with beta-thalassemia trait, and with HbF levels in Thais
      with either beta-thalassemia or HbE trait and in African Americans with sickle
      cell anemia."
    explanation: Provides beta-thalassemia-specific evidence that BCL11A 
      variants modulate HbF-related traits.
phenotypes:
- category: Hematological
  name: Microcytic Hypochromic Anemia
  description: >
    Severe anemia with reduced MCV and MCH due to deficient hemoglobin
    synthesis. Hemoglobin levels can fall to 3-7 g/dL in untreated
    beta-thalassemia major.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: hypochromic microcytic anemia
    term:
      id: HP:0004840
      label: Hypochromic microcytic anemia
  evidence:
  - reference: PMID:20492708
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with thalassemia major usually present within the first
      two years of life with severe anemia, requiring regular red blood cell (RBC)
      transfusions."
    explanation: Confirms severe anemia as the defining presentation of 
      thalassemia major.
- category: Hematological
  name: Decreased Mean Corpuscular Volume
  description: >
    MCV typically 55-75 fL in beta-thalassemia trait and even lower
    in thalassemia major.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: decreased mean corpuscular volume
    term:
      id: HP:0025066
      label: Decreased mean corpuscular volume
- category: Hematological
  name: Reticulocytosis
  description: >
    Elevated reticulocyte count reflecting compensatory erythropoietic
    drive, though inappropriately low relative to degree of anemia
    due to ineffective erythropoiesis.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: reticulocytosis
    term:
      id: HP:0001923
      label: Reticulocytosis
- category: Hematological
  name: Erythroid Hyperplasia
  description: >
    Massively expanded erythroid compartment in bone marrow (erythroid
    to myeloid ratio may exceed 1:1) as a compensatory response.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: erythroid hyperplasia
    term:
      id: HP:0012132
      label: Erythroid hyperplasia
- category: Hematological
  name: Persistence of Hemoglobin F
  description: >
    Elevated fetal hemoglobin as a compensatory mechanism. HbF levels
    vary widely depending on genetic modifiers.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: persistence of hemoglobin F
    term:
      id: HP:0011904
      label: Persistence of hemoglobin F
- category: Hematological
  name: Target Cells
  description: >
    Target cells (codocytes) on peripheral blood smear due to
    reduced hemoglobin content and relative membrane excess.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: target cells
    term:
      id: HP:0034280
      label: Target cells
- category: Hematological
  name: Extramedullary Hematopoiesis
  description: >
    Compensatory hematopoiesis in liver, spleen, and paravertebral
    regions due to insufficient bone marrow output.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: extramedullary hematopoiesis
    term:
      id: HP:0001978
      label: Extramedullary hematopoiesis
- category: Gastrointestinal
  name: Splenomegaly
  description: >
    Splenic enlargement from extramedullary hematopoiesis and
    increased erythrocyte destruction.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
- category: Gastrointestinal
  name: Hepatomegaly
  description: >
    Liver enlargement from extramedullary hematopoiesis, iron
    deposition, and chronic hemolysis.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
- category: Gastrointestinal
  name: Cholelithiasis
  description: >
    Pigment gallstones from chronic bilirubin overproduction
    secondary to hemolysis.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: cholelithiasis
    term:
      id: HP:0001081
      label: Cholelithiasis
- category: Metabolic
  name: Jaundice
  description: >
    Unconjugated hyperbilirubinemia from chronic hemolysis.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: jaundice
    term:
      id: HP:0000952
      label: Jaundice
- category: Metabolic
  name: Elevated Serum Ferritin
  description: >
    Increased serum ferritin reflecting tissue iron deposition from
    transfusions and increased intestinal absorption.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: increased circulating ferritin concentration
    term:
      id: HP:0003281
      label: Increased circulating ferritin concentration
- category: Cardiovascular
  name: Cardiomyopathy
  description: >
    Iron-mediated cardiac damage is the leading cause of death in
    transfusion-dependent beta-thalassemia. Manifests as dilated
    cardiomyopathy and heart failure.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
- category: Cardiovascular
  name: Pulmonary Hypertension
  description: >
    Chronic hemolysis depletes nitric oxide, promoting pulmonary
    vasoconstriction and remodeling. Etiology in thalassemia is
    often mixed (pre- and post-capillary).
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: elevated pulmonary artery pressure
    term:
      id: HP:0004890
      label: Elevated pulmonary artery pressure
- category: Skeletal
  name: Frontal Bossing
  description: >
    Skeletal deformity from marrow expansion in flat bones of the
    skull. Classic finding in undertreated thalassemia major.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: frontal bossing
    term:
      id: HP:0002007
      label: Frontal bossing
- category: Skeletal
  name: Osteoporosis
  description: >
    Reduced bone mineral density from marrow expansion, iron
    overload effects on bone, and endocrine dysfunction.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
- category: Growth
  name: Short Stature
  description: >
    Growth retardation from chronic anemia, iron overload-related
    endocrinopathies, and chelation therapy effects.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: short stature
    term:
      id: HP:0004322
      label: Short stature
- category: Endocrine
  name: Delayed Puberty
  description: >
    Hypogonadotropic hypogonadism from iron deposition in the
    pituitary and gonads.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: delayed puberty
    term:
      id: HP:0000823
      label: Delayed puberty
biochemical:
- name: Hemoglobin
  presence: Decreased
  context: Hemoglobin 3-7 g/dL in untreated thalassemia major
- name: HbA2
  presence: Elevated
  context: Elevated to 3.5-7% in beta-thalassemia trait; diagnostic marker
- name: HbF
  presence: Elevated
  context: Variably elevated depending on genotype and modifiers
- name: Serum Ferritin
  presence: Elevated
  context: Reflects iron overload from transfusions and increased absorption
- name: Indirect Bilirubin
  presence: Elevated
  context: From chronic hemolysis
- name: Reticulocytes
  presence: Variable
  context: Elevated but inappropriately low for degree of anemia
genetic:
- name: HBB
  association: Causative
  inheritance:
  - name: Autosomal recessive
  notes: >
    Over 300 mutations in the HBB gene cause beta-thalassemia.
    Beta-zero mutations (e.g., codon 39 C>T, IVS-I-1 G>A) abolish
    beta-globin production. Beta-plus mutations (e.g., IVS-I-110 G>A,
    -28 A>G) reduce production.
  evidence:
  - reference: PMID:20492708
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Beta-thalassemias are caused by point mutations or, more rarely, deletions
      in the beta globin gene on chromosome 11, leading to reduced (beta+) or absent
      (beta0) synthesis of the beta chains of hemoglobin (Hb). Transmission is autosomal
      recessive"
    explanation: Confirms HBB mutations cause beta-thalassemia with autosomal 
      recessive inheritance.
- name: BCL11A
  association: Modifier
  notes: >
    Genetic variants in BCL11A modulate HbF levels and disease severity.
    BCL11A is the major silencer of gamma-globin expression in adult
    erythroid cells.
  evidence:
  - reference: PMID:18691915
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this study, we showed that SNPs in BCL11A were associated with F-cell
      numbers in Chinese with beta-thalassemia trait, and with HbF levels in Thais
      with either beta-thalassemia or HbE trait and in African Americans with sickle
      cell anemia."
    explanation: Supports BCL11A as an HbF modifier in beta-thalassemia 
      populations.
- name: KLF1
  association: Modifier
  notes: >
    KLF1 (EKLF) mutations can increase HbF levels by reducing BCL11A
    expression. KLF1 haploinsufficiency ameliorates beta-thalassemia
    severity.
- name: HBS1L-MYB
  association: Modifier
  notes: >
    Variants in the HBS1L-MYB intergenic region on chromosome 6q23
    are the second major GWAS locus for HbF levels.
treatments:
- name: Regular Red Blood Cell Transfusions
  description: >
    Mainstay of treatment for beta-thalassemia major. Regular
    transfusions maintain hemoglobin above 9-10 g/dL, suppressing
    ineffective erythropoiesis, preventing skeletal deformities,
    and allowing normal growth.
  treatment_term:
    preferred_term: blood transfusion
    term:
      id: MAXO:0000756
      label: blood transfusion
- name: Iron Chelation Therapy
  description: >
    Essential to prevent iron overload from chronic transfusions.
    Agents include deferoxamine (subcutaneous/IV), deferasirox (oral),
    and deferiprone (oral). Cardiac T2* MRI guides chelation intensity.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Hydroxyurea
  description: >
    Induces fetal hemoglobin production, beneficial in beta-thalassemia
    intermedia and as adjunct in thalassemia major to reduce transfusion
    requirements.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Splenectomy
  description: >
    Considered when hypersplenism increases transfusion requirements.
    Carries risk of post-splenectomy sepsis and thrombosis.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Allogeneic Hematopoietic Stem Cell Transplantation
  description: >
    Only established curative therapy. Best outcomes in young patients
    with HLA-matched sibling donors. Pesaro classification guides
    risk stratification.
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: MAXO:0000747
      label: hematopoietic stem cell transplantation
- name: Luspatercept
  description: >
    Recombinant fusion protein that promotes late-stage erythropoiesis
    by trapping TGF-beta superfamily ligands. Reduces transfusion
    burden in transfusion-dependent beta-thalassemia.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:32212518
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The percentage of patients who had a reduction in the transfusion burden
      of at least 33% from baseline during weeks 13 through 24 plus a reduction of
      at least 2 red-cell units over this 12-week interval was significantly greater
      in the luspatercept group than in the placebo group (21.4% vs. 4.5%, P<0.001)."
    explanation: BELIEVE trial demonstrates luspatercept significantly reduces 
      transfusion burden in transfusion-dependent beta-thalassemia.
- name: Gene Therapy (Betibeglogene Autotemcel)
  description: >
    Approved lentiviral gene therapy that adds functional copies of
    modified beta-globin gene to autologous hematopoietic stem cells.
    Can achieve transfusion independence in most patients.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  evidence:
  - reference: PMID:34891223
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Transfusion independence occurred in 20 of 22 patients who could be
      evaluated (91%), including 6 of 7 patients (86%) who were younger than 12 years
      of age."
    explanation: Northstar-2 phase 3 trial demonstrates betibeglogene autotemcel
      achieves transfusion independence in 91% of evaluable patients.
- name: Genetic Counseling
  description: >
    Carrier screening and genetic counseling for at-risk populations.
    Prenatal diagnosis available via chorionic villus sampling.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
references:
- reference: DOI:10.1038/s41467-023-41961-9
  title: Human cellular model systems of β-thalassemia enable in-depth analysis 
    of disease phenotype
  findings: []
- reference: DOI:10.1182/bloodadvances.2022007655
  title: Elevated CDKN1A (P21) mediates β-thalassemia erythroid apoptosis, but 
    its loss does not improve β-thalassemic erythropoiesis
  findings: []
- reference: DOI:10.1182/bloodadvances.2023012010
  title: A human anti-matriptase-2 antibody limits iron overload, α-globin 
    aggregates, and splenomegaly in β-thalassemic mice
  findings: []
- reference: DOI:10.14218/ge.2023.00128
  title: 'Exploring the Impact of Iron Overload on Mitochondrial DNA in β-Thalassemia:
    A Comprehensive Review'
  findings: []
- reference: DOI:10.3324/haematol.2023.283057
  title: Novel potential therapeutics to modify iron metabolism and red cell 
    synthesis in diseases associated with defective erythropoiesis
  findings: []
- reference: DOI:10.3389/fmolb.2023.1248742
  title: A randomized placebo−controlled clinical trial of oral green tea 
    epigallocatechin 3−gallate on erythropoiesis and oxidative stress in 
    transfusion−dependent β−thalassemia patients
  findings: []
- reference: DOI:10.3389/fphys.2024.1346173
  title: The interactions between ineffective erythropoiesis and ferroptosis in 
    β-thalassemia
  findings: []
- reference: DOI:10.3390/cells13110918
  title: Therapeutic Relevance of Inducing Autophagy in β-Thalassemia
  findings: []
- reference: DOI:10.3390/ijms24043995
  title: Managing the Dual Nature of Iron to Preserve Health
  findings: []
- reference: DOI:10.3390/ijms25063400
  title: 'Impact of α-Globin Gene Expression and α-Globin Modifiers on the Phenotype
    of β-Thalassemia and Other Hemoglobinopathies: Implications for Patient Management'
  findings: []
- reference: DOI:10.3390/thalassrep13030017
  title: 'Understanding the Intricacies of Iron Overload Associated with β-Thalassemia:
    A Comprehensive Review'
  findings: []
- reference: DOI:10.3390/thalassrep14040010
  title: 'Thalassemia: Pathophysiology, Diagnosis, and Advances in Treatment'
  findings: []
